News
ChromaDex to Present at the LD Micro Invitational
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12th annual Invitational. This three-day investor conference is expected to feature...
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
The signed agreement establishes beachhead to broadly market and distribute Tru Niagen® to Mainland China's aging population LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, today announced it has...
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
The ChromaDex External Research Program (CERPTM) was honored in the "Nutrition Research Project" category for pioneering research behind Niagen® LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients, a leading news source for the...
ChromaDex Corporation Reports First Quarter 2022 Financial Results
Total net sales of $17.3 million for the three months ended March 31, 2022, up 18% from the prior year, with $14.9 million from Tru Niagen® and gross margin of 61.0% for the quarter. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results...
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs. May 12, 2022 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2022. The financial results will be reported in a press...
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen, Executive Vice President and Chief...
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
ChromaDex's research and development program reaches over 250 material transfer agreements (MTAs) on Niagen® and other ingredients, marking a milestone in NAD+ research LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer...
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
Tru Niagen® Immune is the first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the company's latest product innovation with the U.S....
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
A newly granted continuation patent provides additional intellectual property protection for ChromaDex's Niagen® ingredient and other nicotinamide adenine dinucleotide (NAD) precursors LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that it was...
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results
Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net sales of $17.8 million for the three months ended December 31, 2021, up 15% from the prior year quarter. LOS...